研究室紹介

総合消化器研究室 肝臓グループ

原著論文

M. Tanaka, J. Jeong, C. Thomas, X. Zhang, P. Zhang, J. Saruwatari, R. Kondo, M. J. McConnell, T. Utsumi, Y. Iwakiri. The sympathetic nervous system promotes hepatic lymphangiogenesis, which is protective against liver fibrosis. Am J Pathol 193(12):2182-2202, 2023.


J. Jeong, M. Tanaka, Y. Yang, N. Arefyev, J. DiRito, G. Tietjen, X. Zhang, M. J. McConnell, T. Utsumi, Y. Iwakiri. An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver. Am J physiol Gastrointest Liver Physiol 325(5):379-390, 2023.


M. Kurokawa, T. Hioki , T. Aoyagi, M. Takahashi, K. Imoto, T. Goya, M. Tanaka, M. Kohjima, Y. Ogawa. Clinicopathologic Features of Adult-onset Still's Disease Complicated by Severe Liver Injury.  Intern med. In press. 2023.


A. Kuwano, T. Okui, M. Kohjima, M. Kurokawa, T. Goya, M. Tanaka, T. Aoyagi, M. Takahashi, K. Imoto, S. Tashiro, H. Suzuki, N. Fujita, Y. Ushijima, K. Ishigami, S. Tokunaga, M. Kato, Y. Ogawa. Transcatheter arterial steroid injection therapy improves the prognosis of patients with acute liver failure. Medicine(Baltimore) 102(10):e33090, 2023.


R. Sugimoto, K. Motomura, A. Ooho, Y. Aratake, A. Ueda, T. Senju, Y. Tanaka, M. Yada, K. Tanaka, A. Kuwano, Y. Morita, S. Nagasawa, M. Ooe, T. Mutsuki, T. Yoshimoto, N. Yamashita  , M. Nakashima, T. Hioki, T. Koyanagi, N. Higuchi, T. Nakamura, S. Harada, M. Tanaka, S. Tada, T. Satoh, K. Uchimura, M. Kuniyoshi, M. Nakamuta, M. Kohjima; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. Intern med 61(21):3157-3164, 2022.


R. Sugimoto, K. Motomura, A. Ooho, Y. Aratake, A. Ueda, T. Senju, Y. Tanaka, M. Yada, K. Tanaka, A. Kuwano, Y. Morita, S. Nagasawa, M. Ooe, T. Mutsuki, T. Yoshimoto, N. Yamashita  , M. Nakashima, T. Hioki, T. Koyanagi, N. Higuchi, T. Nakamura, S. Harada, M. Tanaka, S. Tada, T. Satoh, K. Uchimura, M. Kuniyoshi, M. Nakamuta, M. Kohjima; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. Intern med 61(21):3157-3164, 2022.


T. Goya, M. Kurokawa, T. Hioki, T. Aoyagi, M. Takahashi, K. Imoto, S. Tashiro, H. Suzuki, M. Tanaka, M. Kato, M. Kohjima, Y. Ogawa. Elevated pancreatic enzymes associated with acute liver injury were mediated by tumor necrosis factor-alpha signaling. Hepat Mon 22(1):e128106, 2022.


T. Goya, K. Horisawa, M. Udono, Y. Ohkawa, Y. Ogawa, S. Sekiya, A. Suzuki. Direct  conversion of human endothelial cells into liver cancer-forming cells using nonintegrateive episomal vectors. Hepatol Commun 6(7):1725-1740,2022.


K. Imoto, M. Tanaka, T. Goya, T. Aoyagi, M. Takahashi, M. Kurokawa, S. Tashiro, M. Kato, M. Kohjima, Y. Ogawa. Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency. BMC Gastroenterol 22(1):144, 2022.
 
S. Tashiro, M. Tanaka, T. Goya, T. Aoyagi, M. Kurokawa, K. Imoto, A. Kuwano, M. Takahashi, H. Suzuki, M. Kohjima, M. Kato, Y. Ogawa. Pirfenidone attenuates acetaminophen-induced liver injury via suppressing c-Jun N-terminal kinase phosphorylation. Toxicol Appl Pharmacol 434:115817, 2022.
 
T. Goya, K. Imoto, S. Tashiro, T. Aoyagi, M. Takahashi, M. Kurokawa, H. Suzuki, M. Tanaka, M. Kato, M. Kohjima, Y. Ogawa. The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease. Gastroenterol Insights 13(1):20-26, 2022.
 
T. Goya, T. Kurashige, M. Kurokawa, M. Tanaka, T. Aoyagi, M. Takahashi, K. Imoto, S. Tashiro, H. Suzuki, M. Kato, M. Kohjima, Y. Ogawa. The Combination of Nucleotide Analog Therapy and Steroid Pulse Therapy for Acute HBV Infection Effectively Promotes HBV Clearance. Gastroenterol Insights 13(1):1-8, 2022.
 
A. Kuwano, M. Tanaka, H. Suzuki, M. Kurokawa, K. Imoto, S. Tashiro, T. Goya, M. Kohjima, M. Kato, Y. Ogawa. Upregulated expression of hypoxia reactive genes in peripheral blood mononuclear cells from chronic liver disease patients. Biochem Biophys Rep 27:101068, 2021.
 
A. Kuwano, M. Kurokawa, M. Kohjima, K. Imoto, S. Tashiro, H. Suzuki, M. Tanaka, S. Okada, M. Kato, Y. Ogawa. Microcirculatory disturbance in acute liver injury. Exp Ther Med 21(6):596-596, 2021.
 
M. Tanaka, T. Goya, H. Suzuki, M. Takahashi, K. Imoto, M. Kurokawa, S. Tashiro, A. Kuwano, S. Okada, M. Kato, M. Kohjima, K. Kotoh, Y. Ogawa. Hypoxic hepatitis with marked elevation of serum ferritin probably due to activation of intrahepatic macrophages: another form of hypoxic hepatitis hitherto not reported? Acta Gastro Enterologica Belgica 84(2):317-320, 2021.
 
H. Suzuki, M. Kohjima, M. Tanaka, T. Goya, S. Itoh, T. Yoshizumi, M. Mori, M. Tsuda, M. Takahashi, M. Kurokawa, K. Imoto, S. Tashiro, A. Kuwano, M. Kato, S. Okada, M. Nakamuta, Y. Ogawa. Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 8813410, 2021.
 
S. Yoshizaki, K. Yokota, K. Kubota, T. Saito, M. Tanaka, D. J. Konno, T. Maeda, Y. Matsumoto, Y. Nakashima and S. Okada: The beneficial aspects of spasticity in relation to ambulatory ability in mice with spinal cord injury. Spinal Cord 58(5): 537-543, 2020.
 
S. Yoshizaki, K. Kijima, M. Hara, T. Saito, T. Tamaru, M. Tanaka, D. J. Konno, Y. Nakashima and S. Okada: Tranexamic acid reduces heme cytotoxicity via the TLR4/TNF axis and ameliorates functional recovery after spinal cord injury. J Neuroinflammation 16(1): 160, 2019.
 
R. Takei, T. Inoue, N. Sonoda, M. Kohjima, M. Okamoto, R. Sakamoto, T. Inoguchi and Y. Ogawa: Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One 14(10): e0223302, 2019.
 
A. Kuwano, M. Kohjima, H. Suzuki, A. Yamasaki, T. Ohashi, K. Imoto, M. Kurokawa, Y. Morita, M. Kato and Y. Ogawa: Recombinant human soluble thrombomodulin ameliorates acetaminophen-induced liver toxicity in mice. Exp Ther Med 18(2): 1323-1330, 2019.
 
M. Kido-Nakahara, T. Nakahara, N. Furusyo, S. Shimoda, K. Kotoh, M. Kato, J. Hayashi, T. Koyanagi and M. Furue: Pruritus in Chronic Liver Disease: A Questionnaire Survey on 216 Patients. Acta Derm Venereol 99(2):220-221, 2019.
 
K. Imoto, M. Kohjima, T. Hioki, T. Kurashige, M. Kurokawa, S. Tashiro, H. Suzuki, A. Kuwano, M. Tanaka, S. Okada, M. Kato and Y. Ogawa: Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Can J Gastroenterol Hepatol 2019: 6391712, 2019.
 
K. Yasutake, S. Koga, Y. Hokko, M. Ikemoto, Y. Yaguchi, H. Sakai, Y. Murata, K. Ohe, M. Kohjima, M. Nakamuta and M. Enjoji: Relevance of the Mini Nutritional Assessment in cirrhotic liver disease patients. Asia Pac J Clin Nutr 27(2):300-305, 2018.
 
M. Tanaka and Y. Iwakiri: Lymphatics in the liver. Curr Opin Immunol 53:137-142, 2018.
 
J. Saruwatari, C. Dong, T. Utsumi, M. Tanaka, M. McConnell and Y. Iwakiri: Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats. Sci Rep 8(1):17983, 2018.
 
T. Ohashi, M. Kato, A. Yamasaki, A. Kuwano, H. Suzuki, M. Kohjima and Y. Ogawa: Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice. Food Chem Toxicol 118:190-197, 2018.
 
E. Ogawa, N. Furusyo, H. Nomura, K. Dohmen, N. Higashi, K. Takahashi, A. Kawano, K. Azuma, T. Satoh, M. Nakamuta, T. Koyanagi, M. Kato, S. Shimoda, E. Kajiwara and J. Hayashi: Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther 47(1):104-113, 2018.
 
E. Ogawa, N. Furusyo, K. Azuma, M. Nakamuta, H. Nomura, K. Dohmen, T. Satoh, A. Kawano, T. Koyanagi, A. Ooho, K. Takahashi, M. Kato, S. Shimoda, E. Kajiwara and J. Hayashi: Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res 159:143-152, 2018.
 
T. Hirayama, T. Ikegami, A. Honda, T. Miyazaki, S. I. Yara, M. Kohjima, M. Nakamuta and Y. Matsuzaki: Differences in the Serum 4beta-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Intern Med 57(9):1219-1227, 2018.
 
N. Harada, T. Yoshizumi, T. Ikegami, S. Itoh, N. Furusho, M. Kato, S. Shimoda, T. Fukuhara, Y. Soejima and Y. Maehara: Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation. Anticancer Res 38(9):5513-5520, 2018.
 
Y. Okumura, K. Kohashi, H. Wang, M. Kato, Y. Maehara, Y. Ogawa and Y. Oda: Combined primary hepatic neuroendocrine carcinoma and hepatocellular carcinoma with aggressive biological behavior (adverse clinical course): A case report. Pathol Res Pract 213(10):1322-1326, 2017.
 
E. Ogawa, N. Furusyo, H. Nomura, K. Dohmen, N. Higashi, K. Takahashi, A. Kawano, K. Azuma, T. Satoh, M. Nakamuta, T. Koyanagi, M. Kato, S. Shimoda, E. Kajiwara and J. Hayashi: NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol 52(7):845-854, 2017.
 
M. Miyazaki, M. Yada, K. Tanaka, T. Senjyu, T. Goya, K. Motomura, M. Kohjima, M. Kato, A. Masumoto and K. Kotoh: Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World J Gastroenterol 23(29):5379-5385, 2017.
 
M. Kawashima, Y. Hitomi, Y. Aiba, N. Nishida, K. Kojima, Y. Kawai, H. Nakamura, A. Tanaka, M. Zeniya, E. Hashimoto, H. Ohira, K. Yamamoto, M. Abe, K. Nakao, S. Yamagiwa, S. Kaneko, M. Honda, T. Umemura, T. Ichida, M. Seike, S. Sakisaka, M. Harada, O. Yokosuka, Y. Ueno, M. Senju, T. Kanda, H. Shibata, T. Himoto, K. Murata, Y. Miyake, H. Ebinuma, M. Taniai, S. Joshita, T. Nikami, H. Ota, H. Kouno, H. Kouno, M. Nakamuta, N. Fukushima, M. Kohjima, T. Komatsu, T. Komeda, Y. Ohara, T. Muro, T. Yamashita, K. Yoshizawa, Y. Nakamura, M. Shimada, N. Hirashima, K. Sugi, K. Ario, E. Takesaki, A. Naganuma, H. Mano, H. Yamashita, K. Matsushita, K. Yamauchi, F. Makita, H. Nishimura, K. Furuta, N. Takahashi, M. Kikuchi, N. Masaki, T. Tanaka, S. Tamura, A. Mori, S. Yagi, K. Shirabe, A. Komori, K. Migita, M. Ito, S. Nagaoka, S. Abiru, H. Yatsuhashi, M. Yasunami, S. Shimoda, K. Harada, H. Egawa, Y. Maehara, S. Uemoto, N. Kokudo, H. Takikawa, H. Ishibashi, K. Chayama, M. Mizokami, M. Nagasaki, K. Tokunaga and M. Nakamura: Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Hum Mol Genet 26(3):650-659, 2017.
 
A. Yamasaki, N. Umeno, S. Harada, K. Tanaka, M. Kato and K. Kotoh: Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib. J Gastrointest Oncol 7(3):E36-40, 2016.
 
M. Yada, M. Miyazaki, K. Motomura, A. Masumoto, M. Nakamuta, M. Kohjima, R. Sugimoto, Y. Aratake, N. Higashi, S. Morizono, S. Takao, N. Yamashita, T. Satoh, S. Yamashita, M. Kuniyoshi and K. Kotoh: The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis. J Gastrointest Oncol 7(4):615-23, 2016.
 
M. Tanaka and Y. Iwakiri: The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cell Mol Gastroenterol Hepatol 2(6):733-749, 2016.
 
M. Takahashi, S. Harada, H. Suzuki, N. Yamashita, H. Orita, M. Kato and K. Kotoh: Regorafenib could cause sinusoidal obstruction syndrome. J Gastrointest Oncol 7(3):E41-4, 2016.
 
H. Suzuki, S. Harada, S. Takao, M. Takahashi, M. Kato and K. Kotoh: Low-grade elevation of fibrinogen-degradation products is an important parameter to identify acute presentation of autoimmune hepatitis. Scand J Gastroenterol 51(8):986-93, 2016.
 
M. Ohe, T. Mutsuki, T. Goya, S. Yamashita, T. Satoh, M. Kohjima and M. Kato: Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome. Fukuoka Igaku Zasshi 107(10):185-90, 2016.
 
E. Ogawa, N. Furusyo, H. Nomura, K. Takahashi, N. Higashi, A. Kawano, K. Dohmen, T. Satoh, K. Azuma, M. Nakamuta, T. Koyanagi, M. Kato, S. Shimoda, E. Kajiwara and J. Hayashi: Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res 136:37-44, 2016.
 
M. Kuwayama, K. Uchino, K. Takayoshi, M. Komoda, M. Kohjima, M. Nakamuta, S. Momosaki, H. Kusaba, K. Akashi and E. Baba: Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report. Oncol Lett 11(1):85-88, 2016.
 
N. Kubota, T. Kubota, E. Kajiwara, T. Iwamura, H. Kumagai, T. Watanabe, M. Inoue, I. Takamoto, T. Sasako, K. Kumagai, M. Kohjima, M. Nakamuta, M. Moroi, K. Sugi, T. Noda, Y. Terauchi, K. Ueki and T. Kadowaki: Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nat Commun 7:12977, 2016.
 
M. Kohjima, M. Kurokawa, M. Enjoji, T. Yoshimoto, T. Nakamura, T. Ohashi, K. Fukuizumi, N. Harada, Y. Murata, K. Matsunaga, M. Kato, K. Kotoh and M. Nakamuta: Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C. Exp Ther Med 11(5):1781-1787, 2016.
 
M. Enjoji, M. Kohjima, K. Ohtsu, K. Matsunaga, Y. Murata, M. Nakamuta, K. Imamura, H. Tanabe, A. Iwashita, T. Nagahama and K. Yao: Intracellular mechanisms underlying lipid accumulation (white opaque substance) in gastric epithelial neoplasms: A pilot study of expression profiles of lipid-metabolism-associated genes. J Gastroenterol Hepatol 31(4):776-81, 2016.
 
M. Kohjima, T. Yoshimoto, M. Enjoji, N. Fukushima, K. Fukuizumi, T. Nakamura, M. Kurokawa, N. Fujimori, Y. Sasaki, Y. Shimonaka, Y. Murata, S. Koyama, K. Kawabe, K. Haraguchi, Y. Sumida, N. Harada, M. Kato, K. Kotoh and M. Nakamuta: Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol 21(11):3291-9, 2015.
 
M. Kohjima, M. Enjoji, R. Yada, T. Yoshimoto, T. Nakamura, K. Fukuizumi, N. Fukushima, Y. Murata, M. Nakashima, M. Kato, K. Kotoh, K. Shirabe, Y. Maehara, A. Nakajima, Y. Nozaki, A. Honda, Y. Matsuzaki and M. Nakamuta: Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism. Liver Int 35(3):1095-102, 2015.
 
T. Kawaguchi, M. Kohjima, T. Ichikawa, M. Seike, Y. Ide, T. Mizuta, K. Honda, K. Nakao, M. Nakamuta and M. Sata: The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey. J Gastroenterol 50(3):333-41, 2015.
 
T. Ito, L. Lee, M. Hijioka, K. Kawabe, M. Kato, K. Nakamura, K. Ueda, T. Ohtsuka and H. Igarashi: The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan. J Hepatobiliary Pancreat Sci 22(8):574-7, 2015.
 
K. Yasutake, M. Kohjima, M. Nakamuta, K. Kotoh, Y. Murata and M. Enjoji: [Probiotic nutrition therapy for nonalcoholic fatty liver disease]. Fukuoka Igaku Zasshi 105(2):42-7, 2014.
 
K. Yasutake, M. Kohjima, K. Kotoh, M. Nakashima, M. Nakamuta and M. Enjoji: Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 20(7):1756-67, 2014.
 
M. Uchida, T. Ito, T. Nakamura, M. Hijioka, H. Igarashi, T. Oono, M. Kato, K. Nakamura, K. Suzuki, R. Takayanagi and R. T. Jensen: Pancreatic stellate cells and CX3CR1: occurrence in normal pancreas and acute and chronic pancreatitis and effect of their activation by a CX3CR1 agonist. Pancreas 43(5):708-19, 2014.
 
M. Tanaka, K. Tanaka, Y. Masaki, M. Miyazaki, M. Kato, K. Kotoh, M. Enjoji, M. Nakamuta and R. Takayanagi: Intrahepatic microcirculatory disorder, parenchymal hypoxia and NOX4 upregulation result in zonal differences in hepatocyte apoptosis following lipopolysaccharide- and D-galactosamine-induced acute liver failure in rats. Int J Mol Med 33(2):254-62, 2014.
 
K. Tanaka, Y. Masaki, M. Tanaka, M. Miyazaki, M. Enjoji, M. Nakamuta, M. Kato, M. Nomura, T. Inoguchi, K. Kotoh and R. Takayanagi: Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. World J Gastroenterol 20(10):2653-63, 2014.
 
Y. Ohishi, M. Nakamuta, N. Ishikawa, O. Saitoh, H. Nakamura, Y. Aiba, A. Komori, K. Migita, H. Yatsuhashi, N. Fukushima, M. Kohjima, T. Yoshimoto, K. Fukuizumi, M. Ishibashi, T. Nishino, K. Shirabe, A. Taketomi, Y. Maehara, H. Ishibashi and M. Nakamura: Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 49(2):332-42, 2014.
 
T. Nakamura, T. Ito, M. Uchida, M. Hijioka, H. Igarashi, T. Oono, M. Kato, K. Nakamura, K. Suzuki, R. T. Jensen and R. Takayanagi: PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Lab Invest 94(1):63-78, 2014.
 
M. Imamura, B. H. Chang, M. Kohjima, M. Li, B. Hwang, H. Taegtmeyer, R. A. Harris and L. Chan: MondoA deficiency enhances sprint performance in mice. Biochem J 464(1):35-48, 2014.
 
T. Ikegami, T. Yoshizumi, M. Kato, S. Yamamoto, T. Fukuhara, Y. Matsuura, S. Nakamura, S. Itoh, K. Shirabe and Y. Maehara: Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Transplantation 98(9):994-9, 2014.
 
T. Ikegami, A. Honda, T. Miyazaki, M. Kohjima, M. Nakamuta and Y. Matsuzaki: Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. Biochem Biophys Res Commun 446(3):736-40, 2014.
 
M. Tanaka, Y. Masaki, K. Tanaka, M. Miyazaki, M. Kato, R. Sugimoto, K. Nakamura, S. Aishima, K. Shirabe, M. Nakamuta, M. Enjoji, K. Kotoh and R. Takayanagi: Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep 7(2):365-70, 2013.
 
S. Takao, K. Tanaka, M. Miyazaki, M. Tanaka, T. Ohashi, M. Kato, K. Kotoh, S. Aishima and R. Takayanagi: A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible? Clin J Gastroenterol 6(5):386-9, 2013.
 
K. Migita, M. Nakamura, S. Abiru, Y. Jiuchi, S. Nagaoka, A. Komori, S. Hashimoto, S. Bekki, K. Yamasaki, T. Komatsu, M. Shimada, H. Kouno, T. Hijioka, M. Kohjima, M. Nakamuta, M. Kato, K. Yoshizawa, H. Ohta, Y. Nakamura, E. Takezaki, H. Nishimura, T. Sato, K. Ario, N. Hirashima, Y. Oohara, A. Naganuma, T. Muro, H. Sakai, E. Mita, K. Sugi, H. Yamashita, F. Makita, H. Yatsuhashi, H. Ishibashi and M. Yasunami: Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population. PLoS One 8(8):e71382, 2013.
 
M. Kohjima, T. H. Tsai, B. C. Tackett, S. Thevananther, L. Li, B. H. Chang and L. Chan: Delayed liver regeneration after partial hepatectomy in adipose differentiation related protein-null mice. J Hepatol 59(6):1246-54, 2013.
 
M. Kohjima, M. Enjoji, T. Yoshimoto, R. Yada, T. Fujino, Y. Aoyagi, N. Fukushima, K. Fukuizumi, N. Harada, M. Yada, M. Kato, K. Kotoh, M. Nakashima, N. Sakamoto, Y. Tanaka and M. Nakamuta: Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. J Med Virol 85(2):250-60, 2013.
 
T. Ikegami, K. Shirabe, T. Yoshizumi, N. Furusyo, K. Kotoh, M. Kato, S. Shimoda, Y. Soejima, T. Motomura, T. Fukuhara and Y. Maehara: Impact of conversion from pegylated interferon-alpha2b to interferon-alpha2a for treating recurrent hepatitis C after liver transplantation. Transplantation 95(6):e38-42, 2013.
 
T. Ikegami, K. Shirabe, T. Fukuhara, N. Furusyo, K. Kotoh, M. Kato, S. Shimoda, S. Aishima, Y. Soejima, T. Yoshizumi and Y. Maehara: Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. Hepatol Res 43(6):621-9, 2013.
 
T. Fujino, Y. Aoyagi, M. Takahashi, R. Yada, N. Yamamoto, Y. Ohishi, A. Nishiura, M. Kohjima, T. Yoshimoto, K. Fukuizumi, M. Nakashima, M. Kato, K. Kotoh, M. Nakamuta and M. Enjoji: Association of ITPA polymorphism with outcomes of peginterferon-alpha plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 4(3):54-60, 2013.
 
K. Yasutake, M. Kohjima, M. Nakashima, K. Kotoh, M. Nakamuta and M. Enjoji: Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract 2012:859697, 2012.
 
K. Yasutake, M. Bekki, M. Ichinose, M. Ikemoto, T. Fujino, T. Ryu, Y. Wada, Y. Takami, H. Saitsu, M. Kohjima, K. Fukuizumi, M. Nakashima, M. Nakamuta and M. Enjoji: Assessing current nutritional status of patients with HCV-related liver cirrhosis in the compensated stage. Asia Pac J Clin Nutr 21(3):400-5, 2012.
 
H. Ogino, K. Nakamura, T. Iwasa, E. Ihara, H. Akiho, Y. Motomura, K. Akahoshi, H. Igarashi, M. Kato, K. Kotoh, T. Ito and R. Takayanagi: Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. J Gastroenterol 47(4):366-76, 2012.
 
Y. Niina, N. Fujimori, T. Nakamura, H. Igarashi, T. Oono, K. Nakamura, M. Kato, R. T. Jensen, T. Ito and R. Takayanagi: The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 6(3):287-94, 2012.
 
M. Nakamuta and M. Kohjima: [Lipid metabolism-related gene expression in hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi 109(4):555-62, 2012.
 
M. Miyazaki, M. Kato, M. Tanaka, K. Tanaka, S. Takao, M. Kohjima, T. Ito, M. Enjoji, M. Nakamuta, K. Kotoh and R. Takayanagi: Antithrombin III injection via the portal vein suppresses liver damage. World J Gastroenterol 18(16):1884-91, 2012.
 
M. Miyazaki, M. Kato, K. Tanaka, M. Tanaka, M. Kohjima, K. Nakamura, M. Enjoji, M. Nakamuta, K. Kotoh and R. Takayanagi: Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 5(3):729-33, 2012.
 
K. Kotoh, M. Fukushima, Y. Horikawa, S. Yamashita, M. Kohjima, M. Nakamuta and M. Enjoji: Serum albumin is present at higher levels in alcoholic liver cirrhosis as compared to HCV-related cirrhosis. Exp Ther Med 3(1):72-75, 2012.
 
M. Enjoji, K. Yasutake, M. Kohjima and M. Nakamuta: Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol 2012:925807, 2012.
 
M. Enjoji, M. Kohjima, K. Kotoh and M. Nakamuta: Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments. Int J Hepatol 2012:264017, 2012.
 
M. Toyoda, A. Kitaoka, K. Machida, T. Nishinakagawa, R. Yada, M. Kohjima, M. Kato, K. Kotoh, N. Sakamoto, G. Shiota, M. Nakamuta, M. Nakashima and M. Enjoji: Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. Int J Mol Med 27(5):619-24, 2011.
 
M. Nakamuta, T. Fujino, R. Yada, Y. Aoyagi, K. Yasutake, M. Kohjima, K. Fukuizumi, T. Yoshimoto, N. Harada, M. Yada, M. Kato, K. Kotoh, A. Taketomi, Y. Maehara, M. Nakashima and M. Enjoji: Expression profiles of genes associated with viral entry in HCV-infected human liver. J Med Virol 83(5):921-7, 2011.
 
M. Miyazaki, M. Tanaka, A. Ueda, T. Yoshimoto, M. Kato, M. Nakamuta, K. Kotoh and R. Takayanagi: Acute liver failure caused by drug-induced hypersensitivity syndrome associated with hyperferritinemia. World J Gastroenterol 17(44):4928-31, 2011.
 
M. Miyazaki, M. Kato, M. Tanaka, K. Tanaka, S. Takao, M. Kohjima, T. Ito, M. Enjoji, M. Nakamuta, K. Kotoh and R. Takayanagi: Contrast-enhanced ultrasonography using Sonazoid to evaluate changes in hepatic hemodynamics in acute liver injury. J Gastroenterol Hepatol 26(12):1749-56, 2011.
 
K. Kotoh, M. Kato, M. Kohjima, M. Tanaka, M. Miyazaki, K. Nakamura, M. Enjoji, M. Nakamuta and R. Takayanagi: Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. Exp Ther Med 2(2):195-199, 2011.
 
H. Kawate, A. Taketomi, T. Watanabe, M. Nomura, M. Kato, R. Sakamoto, T. Ikegami, Y. Soejima, Y. Maehara and R. Takayanagi: Hypophosphatemic osteomalacia as a long-term complication after liver transplantation. Transplantation 91(1):e6-8, 2011.
 
S. Itaba, Y. Iboshi, K. Nakamura, H. Ogino, Y. Sumida, A. Aso, S. Yoshinaga, H. Akiho, H. Igarashi, M. Kato, K. Kotoh, T. Ito and R. Takayanagi: Low-frequency of bacteremia after endoscopic submucosal dissection of the stomach. Dig Endosc 23(1):69-72, 2011.
 
N. Higuchi, M. Kato, M. Tanaka, M. Miyazaki, S. Takao, M. Kohjima, K. Kotoh, M. Enjoji, M. Nakamuta and R. Takayanagi: Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease. Exp Ther Med 2(6):1077-1081, 2011.
 
N. Higuchi, M. Kato, M. Miyazaki, M. Tanaka, M. Kohjima, T. Ito, M. Nakamuta, M. Enjoji, K. Kotoh and R. Takayanagi: Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver. J Cell Biochem 112(1):30-8, 2011.
 
T. Fujino, M. Nakamuta, Y. Aoyagi, M. Kohjima, T. Satoh, M. Fukuda, H. Ishibashi, H. Yatsuhashi and M. Enjoji: Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin. Med Sci Monit 17(12):Cr687-91, 2011.
 
M. Yada, A. Masumoto, N. Yamashita, K. Motomura, T. Koyanagi and S. Sakamoto: Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol 16(12):1506-11, 2010.
 
M. Nakamuta, T. Fujino, R. Yada, K. Yasutake, T. Yoshimoto, N. Harada, M. Yada, N. Higuchi, M. Kato, M. Kohjima, A. Taketomi, Y. Maehara, T. Nishinakagawa, K. Machida, K. Matsunaga, M. Nakashima, K. Kotoh and M. Enjoji: Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 48(1):22-8, 2010.
 
M. Miyazaki, M. Kato, M. Tanaka and R. Takayanagi: High-density lipoprotein cholesterol improves the model for end-stage liver disease scoring system for prognostic prediction of acute liver failure. Scand J Gastroenterol 45(4):506-8, 2010.
 
K. Kotoh and R. Takayanagi: [A new treatment strategy for fulminant hepatic failure with transcatheter arterial steroid injection therapy]. Fukuoka Igaku Zasshi 101(6):109-18, 2010.
 
K. Kotoh, M. Kato, M. Kohjima, M. Nakamuta and M. Enjoji: A new treatment strategy for acute liver failure. World J Hepatol 2(11):395-400, 2010.
 
M. Kohjima, Y. Sun and L. Chan: Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model. Endocrinology 151(4):1532-40, 2010.
 
K. Gotoh, Y. Tanaka, A. Nishikimi, R. Nakamura, H. Yamada, N. Maeda, T. Ishikawa, K. Hoshino, T. Uruno, Q. Cao, S. Higashi, Y. Kawaguchi, M. Enjoji, R. Takayanagi, T. Kaisho, Y. Yoshikai and Y. Fukui: Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. J Exp Med 207(4):721-30, 2010.
 
T. Fujino, M. Nakamuta, R. Yada, Y. Aoyagi, K. Yasutake, M. Kohjima, K. Fukuizumi, T. Yoshimoto, N. Harada, M. Yada, M. Kato, K. Kotoh, A. Taketomi, Y. Maehara, M. Nakashima and M. Enjoji: Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver. Hepatol Res 40(9):923-9, 2010.
 
M. Enjoji, K. Machida, M. Kohjima, M. Kato, K. Kotoh, K. Matsunaga, M. Nakashima and M. Nakamuta: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 9:29, 2010.
 
S. L. Samson, M. Kohjima and L. Chan: A fine balance: an autoregulatory gene therapy approach to treat obesity and achieve energy homeostasis. Gene Ther 16(10):1175-7, 2009.
 
M. Nakamuta, R. Yada, T. Fujino, M. Yada, N. Higuchi, M. Tanaka, M. Miyazaki, M. Kohjima, M. Kato, T. Yoshimoto, N. Harada, A. Taketomi, Y. Maehara, M. Koga, T. Nishinakagawa, M. Nakashima, K. Kotoh and M. Enjoji: Changes in the expression of cholesterol metabolism-associated genes in HCV-infected liver: a novel target for therapy? Int J Mol Med 24(6):825-8, 2009.
 
M. Nakamuta, T. Fujino, R. Yada, M. Yada, K. Yasutake, T. Yoshimoto, N. Harada, N. Higuchi, M. Kato, M. Kohjima, A. Taketomi, Y. Maehara, M. Nakashima, K. Kotoh and M. Enjoji: Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. Int J Mol Med 23(5):603-8, 2009.
 
K. Kotoh, A. Ueda, M. Tanaka, M. Miyazaki, M. Kato, M. Kohjima, M. Enjoji, M. Nakamuta and R. Takayanagi: A high prevalence of extreme hyperferritinemia in acute hepatitis patients. Hepat Med 1:1-8, 2009.
 
M. Kohjima, M. Enjoji, N. Higuchi, M. Kato, K. Kotoh, M. Nakashima and M. Nakamuta: The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol Anim 45(1-2):6-9, 2009.
 
T. Ikegami, A. Taketomi, Y. Soejima, T. Yoshizumi, T. Fukuhara, K. Kotoh, S. Shimoda, M. Kato and Y. Maehara: The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplant Proc 41(10):4246-52, 2009.
 
M. Enjoji, R. Yada, T. Fujino, T. Yoshimoto, M. Yada, N. Harada, N. Higuchi, M. Kato, M. Kohjima, A. Taketomi, Y. Maehara, M. Nakashima, K. Kotoh and M. Nakamuta: The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol Int 3(3):490-6, 2009.

pagetop